Company Overview

INmune Bio Inc. is a publicly traded biotechnology company focused on developing therapies that target the innate immune system to treat neurodegenerative diseases and cancer. The company operates within the biopharmaceutical and immunotherapy industries, with a strategic emphasis on conditions where chronic inflammation or immune dysfunction is a key disease driver. Its primary revenue drivers are research and development activities related to its clinical-stage drug candidates rather than commercial product sales, as the company does not currently have approved therapies on the market.

The company’s core positioning centers on selectively modulating immune pathways rather than broadly suppressing immune function, which it believes may offer improved safety and efficacy. INmune Bio was founded in 2015 and became publicly listed on the NASDAQ Capital Market under the ticker INMB. Since inception, the company has evolved from a platform-based immunology concept into a clinical-stage organization with programs in both neuroinflammation and oncology.

Business Operations

INmune Bio’s operations are organized around two primary development programs: INB03 (previously known as XPro1595) for neuroinflammatory and neurodegenerative diseases, and INKmune for oncology applications. INB03 is a selective tumor necrosis factor (TNF) inhibitor designed to neutralize soluble TNF without affecting transmembrane TNF, with development efforts focused primarily on Alzheimer’s disease and related neurodegenerative conditions. INKmune is a natural killer (NK) cell priming platform intended to enhance the patient’s innate immune response against cancer.

The company’s activities are predominantly research- and development-focused, with clinical trials conducted in the United States and select international locations. INmune Bio does not currently report commercial revenue and relies on equity financing to fund operations. Data inconclusive based on available public sources regarding any material revenue contribution from licensing or partnership agreements.

Strategic Position & Investments

Strategically, INmune Bio is focused on advancing late-stage clinical trials for INB03 in neurodegenerative diseases while progressing INKmune through oncology-focused clinical development. The company’s growth strategy centers on demonstrating clinical efficacy in targeted patient subpopulations, which management believes could support regulatory approval and potential future commercialization or partnering opportunities.

INmune Bio has historically emphasized internal development rather than large-scale acquisitions. It does not report a broad portfolio of subsidiaries or significant equity investments in external companies. Data inconclusive based on available public sources regarding any material acquisitions, joint ventures, or minority investments beyond routine clinical and research collaborations.

Geographic Footprint

INmune Bio is headquartered in Boca Raton, Florida, which serves as its primary executive and administrative center. The company’s operational footprint is concentrated in North America, particularly the United States, where most of its research oversight, regulatory interaction, and clinical trial coordination occur.

International activities are primarily limited to clinical research and scientific collaboration rather than large-scale commercial operations. The company has disclosed engagement with international clinical sites and research partners, but it does not maintain a broad global commercial presence. Data inconclusive based on available public sources regarding permanent operational facilities outside the United States.

Leadership & Governance

INmune Bio is led by a management team with experience in immunology, biotechnology, and clinical development. The leadership emphasizes a science-driven approach focused on precision immune modulation and disciplined capital allocation to advance clinical programs.

Key executives include:

• Raymond J. Tesi, M.D. – Chief Executive Officer
• Michael J. Davidson – Chief Financial Officer
• Erik S. Grohn – Chief Operating Officer
• Nidal H. Almasri, Ph.D. – Chief Scientific Officer

The board and executive team articulate a strategic vision centered on translating immune science into disease-modifying therapies, with governance practices aligned to U.S. public company standards.

Verification Requirements